RT @RichardPAConway: Warren et al. TYK2i deucravacitinib in plaque psoriasis at 2 years. Sustained efficacy. No new safe
Tweet Content
Warren et al. TYK2i deucravacitinib in plaque psoriasis at 2 years. Sustained efficacy. No new safety signals seen. @RheumNow #ACR22 Abstr#2134 https://t.co/5SGKKrvwbc https://t.co/ynvfZiOrsp
Links
Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Resul…
https://acrabstracts.org/abstract/deucravacitinib-long-term-efficacy-and-safety…
Show on Archive Page
On
Display in Search Results
On
PDQ
Off